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Sunday, June 1, 2008
03:30 pm – 05:30 pm Registration
05:30 pm – 06:00 pm Welcome and conference overview
06:00 pm – 07:00 pm The Challenge of Providing an Effective, but Technically Complex,
Vaccine to the Developing World
Emilio Emini, Wyeth Pharmaceuticals, USA
07:00 pm – 08:00 pm Reception
08:00 pm – 10:00 pm Opening Dinner and entertainment
IMPORTANT ANNOUNCEMENTS
•  Audiotaping, videotaping and photography of presentations are strictly prohibited.
•  Speakers – Please leave at least 5 minutes for questions and discussion.
•  Please do not smoke at any conference functions.
•  Turn your cellular telephones to vibrate or off during technical sessions.
•  Be sure to make any corrections to your name/contact information on the Master
Participant List or confirm that the listing is correct.  A corrected copy will be sent to all
participants after the conference.
Monday, June 2, 2008
07:00 am – 08:30 am Breakfast
08:30 am – 10:30 am Session I:  Immune System Function and Its Quantitation
(Sponsored by Merck & Co., Inc.)
Session Chair:
David Weiner, University of Pennsylvania School of Medicine
08:30 am – 09:00 am Human Monoclonal Antibodies and Analytic Vaccinology
Antonio Lanzavecchia, Institute for Research in Biomedicine, Switzerland
09:00 am – 09:30 am Utilizing Influenza Vaccination to Rapidly Clone High Affinity Human
Monoclonal Antibodies and to Test the Concept of Original Antigenic
Sin
Jens Wrammert, Emory University School of Medicine, USA
09:30 am – 10:00 am Anti-viral Immune Responses in Lymph Nodes
Ulrich H. von Andrian, Harvard Medical School, USA
10:00 am – 10:30 am Immunological Response to new DNA vaccines
David Weiner, University of Pennsylvania School of Medicine, USA
10:30 am – 11:00 am Break
(Sponsored by Bioreliance)
11:00 am – 11:30 am The First Clinical Efficacy Trial of an Adenovirus Type 5-Based HIV-1
 Vaccine:  The STEP Study
Danilo Casimiro, Merck & Co., Inc., USA
11:30 am – 12:00 pm Quality Issues: The Good-Enough Vaccine
Phil Minor, NIBSC, UK
12:00 pm – 12:45 pm New Methods for Detecting Adventitious Agents
David Onions, BioReliance Corporation, USA
12:45 pm – 01:30 pm Lunch
01:30 pm – 03:30 pm Ad hoc sessions, free time
03:30 pm – 06:00 pm Session II:  Virus and Replicon Vectored Vaccines
(Sponsored by GE Healthcare - WAVE Products Group)
Session Chairs:
Manuel Carrondo, IBET
Alexander von Gabain, Intercell AG
03:30 pm – 04:00 pm Towards a Therapeutic Hepatitis C Vaccine – a Preclinical and Clinical
Learning Curve
Alexander von Gabain, Intercell AG, Austria
04:00 pm – 04:30 pm Delivery Devices and Approaches for Pre-Clinical and Clinical HIV 
Immunization
Britta Wahren, Karolinska Institute and Swedish Institute for Infectious
 Disease Control (SMI), Stockholm, Sweden
04:30 pm – 05:00 pm Flavivirus Capsid Deletion Mutants as a New Vaccine Approach
Christian Mandl, Medical University Vienna, Austria
Monday, June 2, 2008 (continued)
05:00 pm – 05:30 pm Viral Vectors – Coupling Innate Signals to Antigen Expression and 
Presentation
Peter Liljeström, Karolinska Institute Stockholm, Sweden
05:30 pm – 06:00 pm VEEV Replicon-Based Vaccines used in Heterologous Prime Boost 
Strategies Induce Lifelong Protection from Prostate Cancer and
Therapy of Cervical Cancer in Mice and Robust Cell-Mediated
Immunity in Rhesus Macaques
W. Martin Kast, University of Southern California, USA
06:00 pm – 06:30 pm Break
(Sponsored by Pall Life Sciences)
06:30 pm – 08:30 pm Session III:  Emergent & Emergency Vaccines
Session Chair:
Manon Cox, Protein Sciences Corp.
06:30 pm – 07:00 pm Efficient and Economical Influenza Vaccines
Alan Shaw, VaxInnate, USA
07:00 pm – 07:30 pm Flublok, A High Dose Recombinant Influenza Vaccine
Manon Cox, Protein Sciences, USA
07:30 pm – 08:00 pm Challenges and Solutions for the Next Generation of Vaccines:  
Development of Cell Culture-based Live Attenuated Influenza Vaccine
Jonathan Liu, MedImmune, Inc., USA
08:00 pm – 08:30 pm Toward the Development of a SARS Vaccine
Jeffrey Ulmer, Novartis Vaccines and Diagnostics, USA
08:30 pm – 09:30 pm Dinner
09:30 pm – 11:00 pm Poster Reception
Tuesday, June 3, 2008
07:00 am – 08:30 am Breakfast
08:30 am – 10:30 am Session IV: Conjugate Vaccines
Session Chair:
George Siber, Consultant
08:30 am – 09:00 am Analytical and Manufacturing Challenges in Preparation of Bacterial 
Polysaccharide Conjugates
Carl Frasch, Frasch Biologics Consulting, USA
09:00 am – 09:30 am Development of Validated Assays for Measuring the Human Antibody 
Response to Polysaccharide Conjugate Vaccines
Helena Käyhty, National Public Health Institute, Finland
09:30 am – 10:00 am The Human Immune Response to Polysaccharides and Conjugates
David Goldblatt, University College London, UK
10:00 am – 10:30 am The Impact of Polysaccharide Conjugate Vaccines
George Siber, Consultant, USA 
10:30 am – 11:00 am Break
(Sponsored by Artelis)
11:00 am – 11:30 am Regulatory Issues Associated with the Development of a
Comprehensive Meningococcal Vaccine
Ian Feavers, NIBSC, UK
11:30 am – 12:00 pm  TB Vaccine Development and Manufacturing
Jerald Sadoff, Aeras Global TB Vaccine Foundation, USA
(Being presented by Walter Kallaur)
12:00 pm – 12:30 pm Evaluating Novel Cell Substrates for use in Vaccine Manufacture
Phil Krause, FDA/CBER, USA
12:30 pm – 01:00 pm Epitode Driven GAIA HIV Vaccine Development:  An Update
Annie De Groot, EpiVax, Inc., USA
01:00 pm – 02:00 pm Lunch
02:00 pm – 04:00 pm Session V:  Adjuvants & Formulation
Session Chair:
Nathalie Garçon, GlaxoSmithKline Biologicals
02:00 pm – 02:30 pm The Improved ISCOMATRIX® Adjuvant
Debbie Drane, CSL Ltd., Australia
02:30 pm – 03:00 pm Adjuvanted Plasmid DNA-Based Vaccines
Alain Rolland, Vical Inc., USA
03:00 pm – 03:30 pm Exploiting Glycoengineered Yeast for the Development of Next
Generation Vaccines
Robert Davidson, GlycoFi, USA
03:30 pm – 04:00 pm Enhancing Vaccine Immunogenicity Through use of CpG TLR9
Agonists and Other Adjuvants
Risini Weeratna, Coley Pharmaceutical Group, Canada
Tuesday, June 3, 2008 (continued)
04:00 pm Ad hoc sessions, free time for those not going on optional excursion.
Those going on optional excursion should meet at 4:20 in hotel lobby for 4:30
departure.
04:30 pm Optional Excursion/Dinner to Tavira where one can visit the medieval castle
and old Moorish town. Dinner will be on your own and the buses will return
to the hotel after dinner.
Participants not going on the optional excursion will have dinner on
their own either at the hotel or in a local restaurant.
Wednesday, June 4, 2008
07:00 am – 08:30 am Breakfast
08:30 am – 11:00 am Session VI:  Characterization of Complex Biologicals
Session Chairs:
Robert Sitrin, Merck & Co., Inc.
08:30 am – 09:00 am Quality Assessment of CervarixTM, GSK'S Cervical Cancer Vaccine, 
Manufactured with the Baculovirus Expression Vector System (BEVS)
Marguerite Deschamps, GlaxoSmithKline, Belgium
09:00 am – 09:30 am Characterization of Conjugate Vaccines
Rasappa Arumugham, Wyeth Vaccines R&D, USA
09:30 am – 10:00 am Characterization of Adenoviral Vector-Based Vaccines
Katey Einterz Owen, Merck & Co., Inc., USA
10:00 am – 10:30 am Focus on Aggregation:  Causes, Impact & Characterization
John Philo, Alliance Protein Laboratories, USA
10:30 am – 11:00 am Developing In-Vitro Potency Assays to Monitor Process Development
and Stability for Subunit Vaccine
Ying Zhang, Wyeth Vaccines R&D, USA  
11:00 am– 11:30 am Break
(Sponsored by GlaxoSmithKline Biologicals)
11:30 am – 12:00 pm Challenge of Filing 4 New Vaccines at Once
Keith Chirgwin, Merck & Co., Inc., USA
12:00 pm – 12:30 pm PATH: Narrowing the Immunization Gap
John Boslego, PATH, USA
12:30 am – 01:00 pm Viral Vectors for Genetic Vaccination: Strategies, Vector Design and 
Production
Juan Asenjo, University of Chile, Chile
01:00 pm – 02:00 pm Lunch
02:00 pm – 04:00 pm Ad hoc sessions, free time
04:00 pm – 06:10 pm Session VII: VLP's & Inactivated Vaccines
(Sponsored by Probiogen)
Session Chairs:
Octavio Ramirez, UNAM, Mexico
Kathrin U. Jansen, Wyeth Vaccine Research
04:00 pm – 04:30 pm Controlling in vitro Assembly of Virus-like Particles:  From Theory to 
Example(s)
Adam Zlotnick, University of Oklahoma Health Sciences Center, USA
04:30 pm – 05:00 pm Virus-Like Particles as Vaccine Platforms
Bryce Chackerian, University of New Mexico, USA
05:00 pm – 05:30 pm Alternate Rotavirus Vaccines:  Inactivated Virus and VLPs
Margaret Conner, Baylor College of Medicine, USA
Wednesday, June 4, 2008 (continued)
05:30 pm – 05:50 pm Towards a Respiratory Syncytial Virus Vaccine Using Recombinant F 
Protein Transiently Expressed in Mammalian Cells
Sophie Nallet, École Polytechnique Fédérale de Lausanne (EPFL),
Switzerland
05:50 pm – 06:10 pm A Selective Recovery Methodology for the Clarification of Lipid-Envelope 
Virus-like Particles from S. Cerevisiae
Gaik Sui Kee, University College London, UK
06:10 pm – 06:40 pm Break
06:40 pm – 07:10 pm Considerations for use of the “Animal Efficacy Rule”
Karen Goldenthal, Consultant, USA
07:10 pm – 07:40 pm De-risking Vaccine Development: Correlates of Success
Fiona MacLaughlin, The Wellcome Trust, UK
07:40 pm – 08:00 pm AGE1.CR – A Well Characterized Cell Substrate Designed for Production
Vector Based Vaccines
Volker Sandig, ProBioGen AG, Germany
08:00 pm – 09:15 pm Dinner
09:15 pm – 11:00 pm Poster Reception
Thursday, June 5, 2008
07:00 am – 08:30 am Breakfast
08:30 am –10:30 am Session VIII: Veterinary Vaccines:  Lessons to Learn for Human
Vaccine Development
(Sponsored by Merial Ltd.)
Session Chair:
Robert Nordgren, Merial Limited
08:30 am –09:00 am Emerging Diseases, Zoonoses and Vaccines to Control Them
Paul-Pierre Pastoret, World Organization for Animal Health, France
09:00 am –09:30 am Avian Influenza Vaccine Development: Application Technology
Platforms, Field Use and Predictors of Protection
David E. Swayne, US Department of Agriculture, USA
09:30 am –10:00 am Use of Alternate Hosts in the Modeling of Immune Profiling and
Vaccine Recognition
Lorne Babiuk, University of Saskatchewan, Canada
10:00 am –10:30 am Use of Plasmid DNA Vaccine to Treat Melanoma in Dogs
Jedd Wolchok, Memorial Sloane Kettering Cancer Center, USA
(Being presented by Robert Nordgren, Merial Limited)
10:30 am– 11:00 am Break
11:00 am– 01:00 pm Session IX: Manufacturing of Vaccines
Session Chairs:
John G. Auniņš, Merck & Co., Inc.
Paula Marques Alves, ITQB/IBET
11:00 am– 11:30 am Process Intensification for Large Scale Manufacturing Issues
Jose Castillo, Artelis, Belgium
11:30 am– 12:00 pm Multivalent Vaccines for Control and Eradication of FMD
M. Susana Levy, Biogenesis-Bago S.A., Argentina
12:00 pm– 12:30 pm Manufacturing and Regulatory Challenges During the Approval of the First
                                                   Gene Therapy for Food Animals 
Henry Hebel, VGX Pharmaceuticals, USA
12:30 pm– 12:50 pm Intensifying the Productivity of a Recombinant AD35 Manufacturing
Process Using the PER.C6® Cell Substrate
Alfred Luitjens, Crucell, Netherlands
12:50 pm– 01:10 pm Affinity Chromatography of Cell Culture Derived Vaccinia Virus
Michael Wolff, Max Planck Institute for Dynamics of Complex Technical
Systems, Germany
01:10 pm – 02:10 pm Lunch
02:10 pm – 04:10 pm Ad hoc sessions, free time
Thursday, June 5, 2008 (continued)
04:10 pm – 05:30 pm Session IX: Manufacturing of Vaccines (cont'd)
04:10 pm – 04:30 pm Trouble-Shooting Fermentation and Primary Recovery Manufacturing 
Issues in Order to Optimize Antigen Expression Used as Vaccine 
Candidates Against Infectious Diseases
Timothy Lee, Sanofi Pasteur, Canada
04:30 pm – 04:50 pm Technology Transfer and Process Scale-Up
Bo Arve, Wyeth Pharmaceuticals, USA
04:50 pm – 05:10 pm Predictive Modeling in Rotavirus-like Particles Production:  Improving 
Upstream and Downstream Processing Design
Tiago Vicente, IBET, Portugal
05:10 pm – 05:30 pm Implementation of Disposable Technology in Vaccines
Manufacturing:  An Approach to Extractables/Leachables Studies
Hélène Pora, Pall Life Sciences, France
05:30 pm – 06:00 pm Break
06:00 pm – 08:00 pm Session X: Vaccines in Developing Countries
Session Chair:
Barry Buckland, Merck & Co., Inc.
06:00 pm – 06:30 pm The Development of an Inactivated JE Vaccine for Endemic Countries
Mahima Datla, Biological E, India
06:30 pm – 07:00 pm Chickenguniya incidence and Vaccine Technology
Krishna Ella, Bharat Biotech, India
  
07:00 pm – 07:30 pm Vaccine Development for Developing Countries – Regulatory
Approach in the European Union
Manfred Haase, Consultant, Germany
07:30 pm – 08:00 pm Developing Vaccines for Neglected Diseases
Douglas Holtzman, Bill & Melinda Gates Foundation, USA
08:30 pm – 11:00 pm Banquet & Closing
Friday, June 6, 2008
07:00 am – 10:00 am Breakfast and departure
(hotel check-out is noon)
Poster Presentations
1. Metabolism of avian designer cells during influenza and MVA production
Verena Lohr, Max Planck Institute for Dynamics of Complex Technical Systems, Germany
2. Capturing of cell culture derived influenza viruses by sulphated cellulose membranes – A
promising pseudo-affinity method for influenza vaccine production
Lars Opitz, Max Planck Institute for Dynamics of Complex Technical Systems, Germany
3. Anti-apoptotic action of one protein isolated from Lonomia Obliqua and the mitochondrial
participation
Ronaldo Zucatelli Mendonca, Instituto Butantan, Brazil
4. Influenza A virus-like particles as vaccine: comparison and evaluation of different strategies
Florian Krammer, Institute for Applied Microbiology, Austria
5. Rabies virus glycoprotein (RYGP) expression in drosophila S2 cells and in BHK-21 cell infected by
recombinant semliki forrest virus for vaccine purpose
Pereira CA, Instituto Butantan, Brazil
6. Towards a recombinant vaccine for heartwater
Nontobeko Thema, Agricultural Research Council - Onderstepoort Veterinary Institute, South Africa
7. Cryo-electron microscopy as a tool for imaging, characterization and structural analysis of
biological solutions
Clint Potter, NanoImaging Services, USA
8. Insect cells as an efficient platform for the production of AAV-based vaccines
Marc G. Aucoin, University of Waterloo, Canada
9. Engineering of an E. coli host for production of plasmid biopharmaceuticals
Diana M. Bower, Massachusetts Institute of Technology, USA
10. Rapid deployment plasmid production: combining inducible high yield fermentation process with
novel autolytic plasmid DNA purification
Aaron E. Carnes, Nature Technology Corporation, USA
11. Modified E. Coli B, A superior producer of plasmid DNA compared with E. Coli K
Joseph Shiloach, Biotechnology Lab NIDDK, USA
12. Immunogenic display of diverse peptides on virus-like particles of RNA phage Ms2
David S Peabody, University of New Mexico School of Medicine, USA
13. Novel techniques for characterization of double and triple-layered rotavirus-like particles
Maria Candida M. Mellado, IBET/ITQB-UNL, Portugal
14. Host strain influences on supercoiled plasmid DNA Production in E. Coli; implications for efficient
design of Large scale processes
Sin Yee Yau, The Advanced Centre for Biochemical Engineering, UK
15. Insights into the effects of culture media and metabolites on adenovirus production
Chun Fang Shen, Biotechnology Research Institute, Canada
16. Novel adenovirus 5 vaccine delivery platform which overcomes pre-existing immunity to AD
Frank R. Jones, Etubics Corporation, USA
17. Fermentation strategies for the production of recombinant protein antigens in E. Coli
Willie Sun, Wyeth Pharmaceuticals, USA
18. Critical process parameter to control productivity in helper-dependent adenoviral vector
production
Amine Kamen, Biotechnology Research Institute, Canada
19. Production of yellow fever virus in vero cells grown in serum-free medium
Leda R. Castilho, Federal University of Rio de Janeiro, Brazil
20. Screening of DNA vaccines prototypes encoding antigen targeting sequences against sleeping
sickness
Gabriel A. Monteiro, Institute for Biotechnology and Bioengineering, Portugal
21. On the design and production of more stable and efficient plasmid DNA vectors
Duarte Miguel F Prazeres, IBB-Institute for Biotechnology and Bioengineering, Portugal
22. Vp7 and Vp4 genotyping of bovine group a rotavirus in México. Towards the development of a
recombinant vaccine
William A. Rodríguez-Limas, Universidad Nacional Autónoma de México, México
23. 293 cells: An alternative cell line for PPRV production
Paula Marques Alves, ITQB-UNL/IBET, Portugal
24. Assessment of the thermal stability of Cervarix ™
Diane Doucet, GlaxoSmithKline Biologicals, Belgium
25. The influence of elevated oxygen partial pressure on specific virus productivities in an influenza
vaccine process
Andreas Bock, Max Planck, Germany
26. Rotavirus-Like Particle Production:  Mathematical Modeling Rational Approach for Process
Development
António Roldão, IBET/ITQB-UNL, Portugal
27. Development of a cell culture production platform for cold-adapted live attenuated influenza
vaccine (CAIV) strains of Flumist®: effects and interactions of medium components, trypsin, and
different influenza viruses in process productivity
             Luis Maranga, MedImmune Vaccines, USA
28. Development of a cell culture production platform for cold-adapted live attenuated influenza
vaccine (CAIV) Strains of Flumist®: accelerated development of a fully disposable Phase I clinical
manufacturing process
Luis Maranga, MedImmune Vaccines, USA
29. Capillary electrophoresis for the differentiation of double-layered and triple-layered rotavirus-like
particles
Laura A. Palomares, Instituto de Biotecnología. Universidad Nacional Autónoma de Mexico, Mexico
30. Differential expression and functional analysis of e. ruminantium proteins: identification of
potential antigens for a subunit heartwater vaccine
Isabel Marcelino, ITQB/IBET, Portugal
31. Characterization of a cancer vaccine based on very small size proteoliposome (VSSP) obtained by
different formulation processes.
Vladmir Peña, Center of Molecular Immunology, Cuba
32. The Silver Anniversary of Clinical Protein production from recombinant CHO cell culture
Matt Croughan, Rathmann Professor, Keck Graduate Institute, USA
33. A cell-culture-based platform for viral vaccine production for humans
Marina Etcheverrigaray, Universidad Nacional del Litoral, Argentina
34. Rapid mycoplasma testing: The HYMY™ assay combines amplification of viable mycoplasmas in
broth culture with signal detection by quantitative polymerase chain reaction (QPCR)
David Onions, BioReliance Corporation, USA
35. Comparison of dengue-2 virus production in vero cells under serum-free and serum-containing
conditions
Erica A. Schulze, Federal University of Rio de Janeiro, School of Chemistry, Brazil
36. Perfusion process for human and animal viral vaccine production in a single use stirred tank
bioreactor
Nicholas Havelange, Artelis, Belgium
37. Exploiting lymphatic transport and complement activation in th1 stimulating nanoparticle
vaccines
Jeffrey A. Hubbell, Melody A. Swartz, Ecole Polytechnique Fédérale de Lausanne (EPFL), Switzerland
38. MDCK-based influenza production using Cytodex 3 in a wave bioreactor
Johanna Norberg, GE Healthcare Bio-Sciences AB, Sweden
39. Protection induced by pneumococcal surface protein a (pspa) is enhanced by conjugation to a
streptococcus pneumoniae capsular polysaccharide
Luciana C.C. Leite, Instituto Butantan, Brazil
40. Biodistribution and toxicological safety evaluation of adenovirus type 5 vectored vaccines against
ebola and marburg viruses
Rebecca L. Sheets, Vaccine Research Center, NIAID/NIH, USA
41. Development of a universal influenza vaccine
Walter E. Manger, Merck & Co., Inc., USA
42. Purification of retrovirus vector particles and identification of host-associated proteins by
proteomic analysis
Maria Mercedes Segura, Center of Animal Biotechnology and Gene Therapy (CBATEG), Spain
43. SPR Technology as a Powerful Tool to Accurately Determine Influenza Virus Concentration
Camilla Nilsson, GE Healthcare Bio-Sciences AB, Sweden
(presented by Johanna Norberg, GE Healthcare Bio-Sciences AB)
44. Protective Immune Responses to Pathogenic Influenza Using Consensus DNA Immunogens and
Constant Current Electroporation
Henry Hebel, VGX Pharmaceuticals, USA
45. Development of a BioVeris-based, Quantitative Immunoassay for Assessing the Quality of a
Conjugate Vaccine Candidate
Charlie Chen, Wyeth Research, USA
